June 3rd, 2025 – MEDICAL ALLEY, MINNESOTA
ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH),
and CellReadyTM, today announced that it has awarded a $50,000 G-Rex Grant to LifEngine Animal Health
(LEAH) Laboratories Incorporated, a clinical-stage translational medicine company building living therapies for
pets first, and their people next. Critical to their translational mission, LEAH Labs is building a platform for primary
human T cell engineering and use in dogs. Using gene edited human CAR-T cells, they are the first in the world
to induce remissions in pet dogs with lymphoma using CAR-T cells.
The G-Rex Grant is part of ScaleReady’s $20 million grant program aimed at advancing Cell and Gene Therapy
(CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant support allowing
for expeditious optimization of cell manufacturing processes.
“Winning this G-Rex Grant is a major victory in the puzzle of developing a first-in-class cell therapy,” said Dr.
Wesley A. Wierson, Founder and CEO of LEAH Labs. “This funding will lead us to more cost-effective cell therapy
manufacturing by combining scaled G-Rex® outgrowth with our patented, virus-free manufacturing process,
GeneWeld. Moreover, combining GeneWeld with G-Rex® will increase the throughput of our cell therapy
discovery platform, vital to our goal of bringing cures to pets and people. We are excited to work with ScaleReady
to drive forward innovative solutions in cell therapy discovery and scaled manufacturing.”
“We are eager to support LEAH Labs through the G-Rex Grant program. This is our first recipient that is enrolling
dogs into a B cell lymphoma trial based on a unique manufacturing approach using non-lentiviral, precision gene
editing based allogeneic CAR-T in conjunction with cargo screening technologies. Their program with dogs is
intended to set the stage for eventual application in humans.” said John Wilson, CEO of Wilson Wolf
Manufacturing and co-inventor of G-Rex.
As part of the G-Rex® Grant, LEAH Labs will complete optimization of their G-Rex-based cell expansion process,
further defining the cost of goods for their flagship therapeutic in dogs with lymphoma. Additionally, LEAH Labs
will evaluate a suite of critical reagents from Bio-Techne (R&D Systems) including cytokines, while receiving
exclusive support from ScaleReady’s growing consortium of G-Rex Grant Partners who bring best-in-class tools
and technologies as well as unparalleled knowledge and expertise in cell therapy manufacturing.
About LEAH Labs
LEAH Labs is building living therapies for pets first, and their people next. We’re first focused on bringing to
market Chimeric Antigen Receptor T cell therapy to disrupt the current treatment paradigm for dogs with B cell
lymphoma, the clinical analog of CAR-T curable non-Hodgkin’s lymphoma in humans. Underpinning LEAH Labs’
ability to bring CAR-T to dogs is a patented, virus-free gene integration technology, GeneWeld. Leveraging our
core technology, an unmet need for improved canine cancer therapies, a favorable regulatory environment under
the USDA-CVB, a network of innovative veterinary oncologists, and pet owners eager for the best possible care,
LEAH Labs is uniquely positioned to rapidly iterate and innovate on CAR-T cell therapy in natural cancers like
no one else in the world. This approach allows for a 1,000x reduction in CAR-T cell therapy development and
clinical trial costs when compared to FDA-regulated cell therapies in human patients and will ultimately lead to
rapid identification of better therapies that impact both ends of the leash.
About ScaleReady™
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing
platform that enables the world’s most practical, flexible, scalable, and affordable CGT drug product development
and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is
producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT
drugs.
CGT entities relying on the breadth and scope of ScaleReady’s expertise can expect to save years of time and
millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing Corporation
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy
research, process development, and manufacturing. This is being accomplished through its scalable G-Rex®
technology, which is used throughout the world in CGT applications ranging from basic research to commercial
drug production.
Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and
bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson
Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors,
including right-sized reagent quantities in containers that are tailored to high throughput closed-system
manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or
follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
SOURCE Bio-Techne Corporation
